Boston Scientific Corp. BSX shares jumped 2.8% in premarket trade Wednesday to reach record levels after the company announced first-quarter results which exceeded expectations. The company also raised its outlook for the full year, citing a “robust pipeline” in 2023 and beyond. The net income increased to $300 million or 21 cents per share from $97 millions or 7 cents per share in the previous period. Earnings per share adjusted to exclude nonrecurring items rose from 39 cents, to 47 cents. This beat FactSet’s consensus of 43 cents. MedSurg sales grew by 12.0%, to $3.39 Billion, exceeding the FactSet consensus estimate of $3.16 Billion.